FDA found Jamol Laboratories making a nasal emollient under insanitary conditions and without adequate quality control, lab testing, or process validation.
What happened
FDA inspected Jamol Laboratories' drug manufacturing facility in Emerson, New Jersey, from December 5, 2022, to January 12, 2023. Investigators saw manufacturing in an uncontrolled multipurpose space in disrepair, including a dead insect, an exposed ceiling, inadequate ventilation, and a stained, debris-covered fan surrounded by cardboard in a corridor. The inspection also found CGMP (current good manufacturing practice) violations in the quality unit, laboratory testing, and process validation.
What FDA found
The drug was prepared, packed, or held in an unclean, poorly maintained space that could contaminate it.
Section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A)The quality unit — the group responsible for oversight — had no written procedures for its roles, for investigating out-of-specification results and deviations, and did not make sure batch records were complete.
21 CFR 211.22The test used to identify incoming eucalyptus oil was not specific enough; it did not include the infrared spectroscopy test the USP monograph requires.
21 CFR 211.160(b)The firm did not test every batch of the drug for objectionable microorganisms, and did not assess botanical ingredients for aflatoxins or other mycotoxins.
21 CFR 211.165(b)The firm never validated the manufacturing process and had no ongoing program to show that each lot comes out consistent and of the same quality.
21 CFR 211.100(a)
What FDA wants
FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done, including a retrospective review of product on the U.S. market, testing of retained samples, and a process validation plan. If corrective actions cannot be finished in that time, the firm must state why and give a completion schedule.
Who should pay attention
- brands and repackagers that buy OTC nasal or botanical drug products from contract manufacturers
- companies whose products contain botanical ingredients and need aflatoxin and microbial testing
- drugmakers whose quality units operate without written procedures or complete batch records
This is a summary. Read the original letter on fda.gov.